Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Brentuximab vedotin is a drug immunoconjugate with an antibody targeting CD30, an antigen expressed mainly on Hodgkin's and anaplastic large-cell lymphomas, linked to a potent microtubule inhibitor. In a study involving 45 patients after relapse, 11 complete remissions were observed. Approximat...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2010-11, Vol.363 (19), p.1812-1821 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Brentuximab vedotin is a drug immunoconjugate with an antibody targeting CD30, an antigen expressed mainly on Hodgkin's and anaplastic large-cell lymphomas, linked to a potent microtubule inhibitor. In a study involving 45 patients after relapse, 11 complete remissions were observed.
Approximately 15 to 30% of patients with Hodgkin's lymphoma do not have a long-term remission with conventional therapy,
1
resulting in an estimated 1300 deaths annually in the United States alone.
2
Autologous hematopoietic stem-cell transplantation (ASCT) represents a potentially curative treatment for some patients with recurrent or progressive Hodgkin's lymphoma after failure of initial combination chemotherapy. Unfortunately, ASCT is only effective in approximately 50% of such patients.
3
,
4
Among those who have a relapse after ASCT, overall survival is 55% at 2 years and 32% at 5 years.
5
Because the incidence of Hodgkin's lymphoma peaks during young adulthood, these premature deaths . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa1002965 |